Cheston B. Cunha

ORCID: 0000-0003-4149-9146
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Antibiotic Use and Resistance
  • Antibiotics Pharmacokinetics and Efficacy
  • Bacterial Identification and Susceptibility Testing
  • Pneumonia and Respiratory Infections
  • Antibiotic Resistance in Bacteria
  • Nosocomial Infections in ICU
  • Sepsis Diagnosis and Treatment
  • Legionella and Acanthamoeba research
  • Streptococcal Infections and Treatments
  • Zoonotic diseases and public health
  • Respiratory viral infections research
  • Yersinia bacterium, plague, ectoparasites research
  • Complementary and Alternative Medicine Studies
  • Hematological disorders and diagnostics
  • Influenza Virus Research Studies
  • Vibrio bacteria research studies
  • Urinary Tract Infections Management
  • Viral Infections and Vectors
  • Cerebral Venous Sinus Thrombosis
  • Orthopedic Infections and Treatments
  • Antimicrobial Resistance in Staphylococcus
  • Retinal and Optic Conditions
  • Ocular Diseases and Behçet’s Syndrome
  • Autoimmune and Inflammatory Disorders Research
  • Vaccine Coverage and Hesitancy

Brown University
2014-2025

Rhode Island Hospital
2010-2024

Miriam Hospital
2010-2024

Rutgers, The State University of New Jersey
2019

Providence College
2013-2016

Lifespan
2015

Infectious Disease Consultants
2013

John Brown University
2009-2013

Warren Alpert Foundation
2013

Hospital São Rafael
2012

Doxycycline is a long-acting/second generation tetracycline antibiotic, and currently one of the most commonly prescribed antibiotics in world, used to treat wide variety infectious agents including susceptible intracellular/zoonotic pathogens [1Cunha BA The pharmacokinetics doxycycline.Postgrad Med Comm. 1979; 1: 43-50Google Scholar, 2Cunha Comer JB Jonas M tetracyclines.Med Clin North Am. 1982; 66: 293PubMed Google 3Cunha Clinical uses tetracyclines.in: Blackwood RK Hlavka JJ Booth JH...

10.1046/j.1469-0691.2000.00058-2.x article EN cc-by-nc-nd Clinical Microbiology and Infection 2000-05-01

Few studies assess the utility of rapid multiplex molecular respiratory panels in adult patients. Previous PCR assays took hours to days from order time result. We analyze clinical impact switching a assay with 3-h test-turnaround-time (TAT).

10.1128/jcm.00861-19 article EN cc-by Journal of Clinical Microbiology 2019-08-09

An abstract is not available for this content. As you have access to content, full HTML content provided on page. A PDF of also in through the 'Save PDF' action button.

10.1017/ice.2022.194 article EN cc-by Infection Control and Hospital Epidemiology 2022-09-14

Abstract Background Piperacillin/tazobactam (TZP)-non-susceptible (NS) but third-generation cephalosporin (3GC)-susceptible (S) Escherichia coli and Klebsiella pneumoniae are increasingly reported in the clinical setting. This phenotype is associated with hyperproduction of β-lactamases, including TEM-1 SHV-1. Tailoring therapy to a 3GC these cases may decrease carbapenem use promote antimicrobial stewardship. However, optimal definitive β-lactam regimen for this unknown. retrospective case...

10.1093/ofid/ofae631.1684 article EN cc-by Open Forum Infectious Diseases 2025-01-29

Background Differences in clinical presentation and outcomes among patients infected with pandemic 2009 influenza A H1N1 (pH1N1) compared to other respiratory viruses have not been fully elucidated. Methodology/Principal Findings retrospective study was performed of all hospitalized at the peak pH1N1 season whom a single virus detected by molecular assay targeting 18 viruses/subtypes (RVP, Luminex xTAG). Fifty-two percent (615/1192) from October, December, had (291 pH1N1; 207 rhinovirus; 45...

10.1371/journal.pone.0024734 article EN cc-by PLoS ONE 2011-09-16

To assess the efficacy and safety of hydroxychloroquine with or without azithromycin) in hospitalized adult patients COVID-19. We utilized a hospital based prospective data registry. The primary end point was to impact azithromycin, on outcome, length hospitalization, time clinical improvement. treatment effects inverse-probability-weighting Cox proportional hazards models. All analyses accounted for age, gender, race, severity admission, days from symptoms onset chronic comorbidities. 36...

10.1016/j.jgar.2020.07.018 article EN cc-by-nc-nd Journal of Global Antimicrobial Resistance 2020-08-05

An abstract is not available for this content so a preview has been provided. Please use the Get access link above information on how to content.

10.1017/ice.2015.283 article EN Infection Control and Hospital Epidemiology 2015-11-26
Coming Soon ...